ABUS

Company Overview — What Does Arbutus Biopharma Corp Do?

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Arbutus Biopharma Corp (ABUS) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO William H. Collier and employs approximately 90 people, headquartered in BURNABY, Pennsylvania. With a market capitalization of $884M, ABUS is one of the notable companies in the Healthcare sector.

Arbutus Biopharma Corp (ABUS) Stock Rating — Reduce (April 2026)

As of April 2026, Arbutus Biopharma Corp receives a Reduce rating with a composite score of 35.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ABUS ranks #2,107 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Arbutus Biopharma Corp ranks #238 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ABUS Stock Price and 52-Week Range

Arbutus Biopharma Corp (ABUS) currently trades at $4.20. The stock lost $0.10 (2.4%) in the most recent trading session. The 52-week high for ABUS is $5.10, which means the stock is currently trading -17.7% from its annual peak. The 52-week low is $2.71, putting the stock 55.1% above its annual trough. Recent trading volume was 2.7M shares, reflecting moderate market activity.

Is ABUS Overvalued or Undervalued? — Valuation Analysis

Arbutus Biopharma Corp (ABUS) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 11.39x, versus the sector average of 2.75x. The price-to-sales ratio is 60.67x, compared to 1.66x for the average Healthcare stock.

At current multiples, Arbutus Biopharma Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Arbutus Biopharma Corp Profitability — ROE, Margins, and Quality Score

Arbutus Biopharma Corp (ABUS) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -64.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -52.3% versus the sector average of -33.1%.

On a margin basis, Arbutus Biopharma Corp reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1170.3% (sector: -66.1%). Net profit margin stands at -1075.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -69.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ABUS Debt, Balance Sheet, and Financial Health

Arbutus Biopharma Corp has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 15.73x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $22M.

ABUS has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Arbutus Biopharma Corp is 53/100, reflecting average volatility within the normal range for its sector.

Arbutus Biopharma Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Arbutus Biopharma Corp reported revenue of $14M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-49M. Gross margin was 100.0%. Operating income came in at $-54M.

In FY 2025, Arbutus Biopharma Corp reported revenue of $14M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-34M. Revenue grew 128.2% year-over-year compared to FY 2024. Operating income came in at $-38M.

In Q3 2025, Arbutus Biopharma Corp reported revenue of $529,000 and earnings per share (EPS) of $-0.04. Net income for the quarter was $-8M. Revenue grew -60.5% year-over-year compared to Q3 2024. Operating income came in at $-9M.

In Q2 2025, Arbutus Biopharma Corp reported revenue of $11M and earnings per share (EPS) of $0.01. Net income for the quarter was $3M. Revenue grew 522.2% year-over-year compared to Q2 2024. Operating income came in at $1M.

Over the past 8 quarters, Arbutus Biopharma Corp has demonstrated a growth trajectory, with revenue expanding from $2M to $14M. Investors analyzing ABUS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ABUS Dividend Yield and Income Analysis

Arbutus Biopharma Corp (ABUS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ABUS Momentum and Technical Analysis Profile

Arbutus Biopharma Corp (ABUS) has a momentum factor score of 52/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ABUS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Arbutus Biopharma Corp (ABUS) ranks #238 out of 838 stocks based on the Blank Capital composite score. This places ABUS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ABUS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ABUS vs S&P 500 (SPY) comparison to assess how Arbutus Biopharma Corp stacks up against the broader market across all factor dimensions.

ABUS Next Earnings Date

No upcoming earnings date has been announced for Arbutus Biopharma Corp (ABUS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ABUS? — Investment Thesis Summary

The quantitative profile for Arbutus Biopharma Corp suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 29/100 indicates premium valuation.

In summary, Arbutus Biopharma Corp (ABUS) earns a Reduce rating with a composite score of 35.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ABUS stock.

Related Resources for ABUS Investors

Explore more research and tools: ABUS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ABUS head-to-head with peers: ABUS vs AZN, ABUS vs SLGL, ABUS vs VMD.